Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Common Equity (2016 - 2026)

OptimizeRx's Common Equity history spans 16 years, with the latest figure at $128.3 million for Q4 2025.

  • On a quarterly basis, Common Equity rose 9.65% to $128.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $128.3 million, a 9.65% increase, with the full-year FY2025 number at $128.3 million, up 9.65% from a year prior.
  • Common Equity hit $128.3 million in Q4 2025 for OptimizeRx, up from $122.3 million in the prior quarter.
  • Over the last five years, Common Equity for OPRX hit a ceiling of $140.8 million in Q2 2022 and a floor of $114.5 million in Q3 2024.
  • Historically, Common Equity has averaged $123.8 million across 5 years, with a median of $123.3 million in 2023.
  • Biggest five-year swings in Common Equity: skyrocketed 186.59% in 2021 and later decreased 17.76% in 2023.
  • Tracing OPRX's Common Equity over 5 years: stood at $131.4 million in 2021, then decreased by 4.01% to $126.1 million in 2022, then increased by 0.35% to $126.6 million in 2023, then fell by 7.55% to $117.0 million in 2024, then increased by 9.65% to $128.3 million in 2025.
  • Business Quant data shows Common Equity for OPRX at $128.3 million in Q4 2025, $122.3 million in Q3 2025, and $119.3 million in Q2 2025.